iForumRx.org
Using shared decision-making tools: Are they worth it?

Using shared decision-making tools: Are they worth it?

November 13, 2020

There’s no denying that shared decision making (SDM) is an effective communication approach for making patient-centered medical decisions across a variety of health conditions. However, while tools for SDM are often useful during patient visits with practitioners, studies have yielded mixed results with regard to patient outcomes.  A new study explores the impact of a SDM tool for anticoagulation selection in patients with atrial fibrillation compared to standard care.

Guest Authors:  Ashley Meredith, PharmD, BCACP, BCPS, CDCES and Chandler Howell, PharmD

Music by Good Talk

A Cause for a PAUSE: Evaluating a Standardized Perioperative DOAC Management Protocol

A Cause for a PAUSE: Evaluating a Standardized Perioperative DOAC Management Protocol

January 31, 2020

One in six patients with atrial fibrillation (AF), or an estimated six million patients worldwide, will require perioperative anticoagulant management this year.  Ambulatory care pharmacists commonly face the scenario where a patient taking a direct oral anticoagulant (DOAC) for AF requires an elective surgery or procedure. Best practices for periprocedural management of DOACs are unclear and current guidelines differ in their recommended approaches. Having a simple, systematic periprocedural DOAC management protocol would be helpful. But would a straightforward protocol that is easily understood by clinicians and patients be safe and effective? The PAUSE study investigators attempt to establish the standard of care.

Guest Authors:  Maggie Faraj, PharmD and Candice Garwood, PharmD, BCPS, BCACP

Music by Good Talk

Secondary Stroke Prevention in A-Fib: Do DOACs PROSPER in High-Risk Patients?

Secondary Stroke Prevention in A-Fib: Do DOACs PROSPER in High-Risk Patients?

November 22, 2019

Several guidelines now recommend direct oral anticoagulants (DOACs) as the preferred anticoagulants for patients with non-valvular atrial fibrillation (a-fib). However, the landmark clinical trials focused largely on the primary prevention of stroke.  Moreover, real-world data using DOACs for secondary prevention is lacking. Many have argued that warfarin might be a better choice in these high-risk patients because it requires routine monitoring and increases the patient’s contact with the healthcare system. Does the choice of anticoagulant make a difference in preventing recurrent stroke?

Guest Authors: Blaire White, PharmD; Amber Cizmic, PharmD, BCACP; and Tish Smith, PharmD, BCACP

Music by Good Talk

Top Ten Things Every Clinician Should Know About the 2018 Antithrombotic Therapy Atrial Fibrillation Guidelines

Top Ten Things Every Clinician Should Know About the 2018 Antithrombotic Therapy Atrial Fibrillation Guidelines

October 12, 2018

The American College of Chest Physicians (ACCP) recently updated their guideline recommendations for the use of antithrombotics for the prevention of stroke in patients with atrial fibrillation (aka the Chest Guidelines).  Find out what's new, who shouldn't receive treatment based on the CHA2DS2-VASc score, and why the guideline panel recommends calculating a patient's SAME-TTR score.

Guest Author:  Dylan Lindsay, PharmD

Music by Good Talk

Podbean App

Play this podcast on Podbean App